Amgen
Stories
-
Amgen announces positive Phase 3 results for dazodalibep in Sjögren's disease
Amgen said the Phase 3 OASIZ-301 study met its primary endpoint, with both 1,500 mg every four weeks and 3,000 mg every 12 weeks regimens showing statistically significant reductions in ESSDAI score versus placebo at Week 48. The company noted improvements in patient-reported dryness and that the most common adverse events were nasopharyngitis, urinary tract infection, hypertension and infusion-related reactions.
-
Amgen posts results of Phase 3 erenumab trial in pediatric chronic migraine
The study, completed with 284 participants, evaluated erenumab in children 6 to <12 years and adolescents 12 to <18 years with chronic migraine. Results were first posted on ClinicalTrials.gov on October 28, 2026.
-
Amgen APPOINTS David W. Gibbs to board of directors
The appointment is effective immediately and Gibbs will serve on the Audit Committee and Compensation and Management Development Committee. The Board will have 13 directors, 12 of whom are independent.
-
Amgen and AstraZeneca report Phase 3 CROSSING trial results for TEZSPIRE in eosinophilic esophagitis
The Phase 3 CROSSING trial showed TEZSPIRE achieved histologic remission in 64.8% (210 mg) and 68.9% (420 mg) of patients at week 24 versus 3.5% on placebo (p<0.001). The Dysphagia Symptom Questionnaire score decreased by 18.8 points (210 mg) and 22.0 points (420 mg) versus 14.7 points on placebo, with reductions sustained through week 52.
-
Amgen registers Phase 3 trial of maridebart cafraglutide versus semaglutide in type 2 diabetes
The study, NCT07866066, plans to enroll 1300 participants and start on November 2, 2026. It plans to compare maridebart cafraglutide once monthly versus semaglutide once weekly as add-on therapy to metformin with or without a sodium-glucose cotransporter-2 inhibitor.
-
Amgen registers Phase 3 study of inebilizumab in primary membranous nephropathy
This study was first posted on ClinicalTrials.gov on October 1, 2026. The study plans to enroll 159 participants and aims to evaluate the efficacy of inebilizumab on PMN disease activity as measured by complete remission.